BioNTech Results Presentation Deck

We intend to expand and accelerate our 10 pipeline development through a mix of targeted in-licensing, strategic collaborations, and M&A mRNA Cancer Vaccines 39 iNeST Fix Vac Next Gen CAR-T/ Neoantigen-based T Cell / TCR-T Therapy Cell Therapies Targeting Cancer CAR, Chimeric antigen receptor; TLR-7, Toll-like receptor 7 Targeted Cancer Antibodies Antibodies + Immunomodulatio TLR-7 Agonist Small Molecule Immunomodulators Next Generation Immunomodulators Bispecifics / Trispecifics ပြီး Ribocytokines Ribomabs Engineered Biologicals Recently announced Kite transaction strengthens our Cell Therapy pipeline and capabilities ww BIONTECH

View entire presentation